CClinicalTrials.gg
WithdrawnNCT03692494Updated Feb 7, 2025

The Effects of Adding Expiratory Muscle Strength Training in Voice Therapy

An interventional study of Standard of care voice therapy and Expiratory muscle strength training (EMST) in Dysphonia and Unilateral Vocal Cord Paralysis, sponsored by University of Miami. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by University of Miami · Not applicable, Interventional, and Treatment

Why this study was withdrawn
PI did decided reorganize the methodology for this study and will resubmit in the future.
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Evaluate if adding expiratory muscle strength training to traditional voice therapy for individuals with dysphonia due to glottal insufficiency improves maximal expiratory pressure, acoustic and aerodynamic measures (i.e. amplitude, maximum phonation time, peak expiratory flow), and voice related quality of life.

02

Conditions studied

  • Dysphonia
  • Unilateral Vocal Cord Paralysis
03

In context

Dysphonia

131 studies on the registry are indexed under Dysphonia; 34 are open to participants now.

Browse Dysphonia studies →

Lead sponsor

University of Miami is the lead sponsor of 820 studies on the registry; 161 are open to participants now.

Of its 111 completed or terminated interventional studies of FDA-regulated products, 93 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Individuals with glottic insufficiency.
  • Adequate cognition evidenced by score of 24 or higher on the Mini-Mental State Examination (MMSE) survey to determine if the subject has the mental capacity to participate in therapy
  • Completed voice combination evaluation with speech pathologists and otolaryngologist.
  • Individuals 18 years of age or older

Exclusion criteria

Exclusion Criteria:

  • Adults unable to consent
  • Non English or Spanish speakers
  • Pregnant women
  • Prisoners
  • Individuals with significant uncontrolled chronic and progressive respiratory diseases including COPD, interstitial lung disease, and cystic fibrosis.
  • Individuals with uncontrolled blood pressure.
  • Individuals with significant GI disease and/or gastroesophageal surgery with the exception of well-controlled GERD.
  • Individuals with a history of abdominal hernia.
  • Individuals with difficulty complying due to neuropsychological dysfunction (e.g., severe depression, psychosis).
  • Individuals with other neurological disorders and/or neuromuscular disease other than Parkinson's Disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Unilateral vocal fold paralysis standard of care voice therapy

    The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques.

    Other: Standard of care voice therapy

  • Experimental
    Unilateral paralysis standard of care voice therapy plus EMST

    The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.

    Other: Standard of care voice therapy · Other: Expiratory muscle strength training (EMST)

  • Experimental
    Parkinson's disease standard of care voice therapy plus EMST

    The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.

    Other: Standard of care voice therapy · Other: Expiratory muscle strength training (EMST)

Interventions

  • OtherStandard of care voice therapy

    Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder

  • OtherExpiratory muscle strength training (EMST)

    EMST150 used at 75% of their maximum expiratory pressure. Participants will be directed to perform 5 sets of 5 breaths, 5 days per week, for 5 weeks, at the pressure threshold established in therapy. Maximum expiratory pressure will then be determined at the beginning of each therapy session and recalibration of the device will be performed if indicated.

06

What researchers measure

Primary outcomes

  1. Maximum expiratory pressure

    Maximum expiratory pressure, in cm of H2O, will be measured to evaluate how much pressure a participant can blow into a respiratory pressure meter.

    Time frame: 16 weeks

  2. Amplitude

    Amplitude of voice, in decibels, will be measured using Voice Range Profile on Kay Pentax CSL and will be compared to gender matched normative values for normal and loud volumes.

    Time frame: 16 weeks

Secondary outcomes

  1. Fundamental frequency

    Fundamental frequency, measured in herz, will be obtained using the Analysis of Dysphonia in Speech and Voice on Kay Pentax Computerized Speech Lab.

    Time frame: 16 weeks

  2. Dynamic pitch range

    Dynamic pitch range will be measured using Voice Range Profile on Kay Pentax Computerized Speech Lab.

    Time frame: 16 weeks

  3. Cepstral Peak Prominence (CPP)

    Cepstral Peak Prominence will be obtained using the Analysis of Dysphonia in Speech and Voice on Kay Pentax Computerized Speech Lab.

    Time frame: 16 weeks

  4. Cepstral spectral index of dysphonia (CSID)

    Cepstral spectral index of dysphonia, will be obtained using the Analysis of Dysphonia in Speech and Voice on Kay Pentax Computerized Speech Lab.

    Time frame: 16 weeks

  5. Voice Handicap Index

    This is quality of life assessment tool quantifying perception of the impact of their vocal disorder on various aspects of lifestyle. It is 30-questions in length and is divided into 3 subscales including emotional, physical, and functional, divided into 10 questions each. Each question scored from 0-4. Total score range from 0-120. Higher score indicates increased handicap.

    Time frame: 16 weeks

  6. Maximum phonation time

    The patient will be asked to inhale deeply and sustain the vowel /a/ at a comfortable loudness level for a many seconds as possible.

    Time frame: 16 weeks

  7. Peak expiratory flow rate

    Peak expiratory flow rate, measured in units of liters per minute, will be measured for purposes of measuring cough function.

    Time frame: 16 weeks

07

Study locations

1 site
  • University of Miami
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03692494
Lead sponsor
University of Miami
Responsible party
Adam Lloyd (Speech Pathologist, University of Miami) — Principal investigator
First posted
Oct 2, 2018
Start date
Apr 1, 2025 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Feb 7, 2025

Study contacts

Adam T Lloyd, SLP-D, MM, MA
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion